Lexaria to Undertake Extensive GLP-1 Study Program to Support Commercial Discussions

Lexaria Bioscience (Nasdaq: LEXX) has announced it will initiate an extensive glucagon-like peptide-1 (GLP-1) study program in 2024 to support prospective commercial partnering with the global pharmaceutical companies. The comprehensive applied research program will evaluate Lexaria’s proprietary DehydraTECH technology for the improved delivery of GLP-1 drugs.

Lexaria recently reported positive results from a human pilot study which demonstrated superior oral delivery performance of the DehydraTECH-enhanced GLP-1 drug semaglutide available commercially in the branded product Rybelsus®. The new studies will work to determine the commercial applicability of DehydraTECH to GLP-1 drugs including semaglutide, liraglutide, and tirzepatide. 

Highlights

Lexaria will undertake a chronic dosing animal study with a targeted start of March/April, 2024, evaluating DehydraTECH formulations of semaglutide and liraglutide, alone and together with DehydraTECH-CBD.

A second human pilot study is targeted to begin in March/April, 2024. Lexaria says this study will evaluate a single dose of oral ingested DehydraTECH-semaglutide capsule. The study will also evaluate an oral (sublingual/buccal) dissolvable DehydraTECH-semaglutide tablet formulation to determine whether GLP-1 drug absorption via this route is effective and well tolerated as an alternative to the conventional oral ingestible route which often causes gastrointestinal side effects.

Lexaria intends to initiate a third human pilot study with a start date in May/June, 2024. The study will evaluate a single dose of oral ingested DehydraTECH-tirzepatide capsules to evaluate tolerability, PK, and blood sugar.

Finally, the company plans to establish a chronic dosing human study in Q3, 2024. The study will compare DehydraTECH-processed semaglutide capsules to DehydraTECH-CBD capsules alone in 70 to 90 pre-diabetic and type-2 diabetic human patients who will be dosed daily using oral DehydraTECH capsules for 12 weeks to evaluate tolerability, PK, weight loss, blood sugar levels and more. 

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Share this article:

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

Share This Article

 

About the Author

Lexaria to Undertake Extensive GLP-1 Study Program to Support Commercial Discussions

Catie Corcoran

Biotech Editor